Signatope (Reutlingen, Germany) develops safety protein biomarker assays that support both preclinical and clinical drug development. Its platform combines immunoaffinity enrichment with sensitive mass spectrometry, enabling precise quantification of a broad range of biomarkers. In partnership with pharmaceutical partners, Signatope leads efforts to qualify biomarkers for drug-induced organ injury at the FDA and EMA, supporting regulatory acceptance and safer drug development.
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot
Copyright © American College of Toxicology. All rights reserved.
You may view the ACT Privacy Policy, Code of Conduct, provide consent to ACT
to email you communications, or unsubscribe to stop receiving further ACT communication.
Privacy Policy | Code of Conduct | Provide Consent | Unsubscribe